ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Plexxikon and Roche have entered a partnership to develop PLX4032, a Plexxikon cancer therapy that is slated for a Phase I clinical trial by the end of the year. Roche will pay Plexxikon $40 million up front and another $6 million in research funding. Plexxikon could receive up to $660 million if all milestones are reached. Separately, Plexxikon has entered a cardiovascular collaboration with the French drug company Servier focused on nonpeptidic inhibitors of renin. This deal could be worth as much as $100 million for Plexxikon.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X